Correction to: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease

Affiliations

¹ The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, 3010, Australia. d.finkelstein@florey.edu.au.
² The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, 3010, Australia.
³ Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
⁴ The Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.
⁵ Elemental Bio-Imaging Facility, The University of Technology Sydney, Broadway, Ultimo, NSW, 2007, Australia.
⁶ Australia Electron Microscope Unit, School of Biosciences, The University of Melbourne, Melbourne, VIC, 3010, Australia.
⁷ Prana Biotechnology Ltd, Parkville, VIC, 3052, Australia.
⁸ Bio21 Institute and Department of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, VIC, 3010, Australia.
⁹ The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, 3010, Australia. rcherny@unimelb.edu.au.
¹⁰ Prana Biotechnology Ltd, Parkville, VIC, 3052, Australia. rcherny@unimelb.edu.au.

Published Erratum

David I Finkelstein et al. Acta Neuropathol Commun. 2021.

. 2021 Sep 29;9(1):161.

doi: 10.1186/s40478-021-01258-8.

¹ The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, 3010, Australia. d.finkelstein@florey.edu.au.
² The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, 3010, Australia.
³ Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
⁴ The Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.
⁵ Elemental Bio-Imaging Facility, The University of Technology Sydney, Broadway, Ultimo, NSW, 2007, Australia.
⁶ Australia Electron Microscope Unit, School of Biosciences, The University of Melbourne, Melbourne, VIC, 3010, Australia.
⁷ Prana Biotechnology Ltd, Parkville, VIC, 3052, Australia.
⁸ Bio21 Institute and Department of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, VIC, 3010, Australia.
⁹ The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, 3010, Australia. rcherny@unimelb.edu.au.
¹⁰ Prana Biotechnology Ltd, Parkville, VIC, 3052, Australia. rcherny@unimelb.edu.au.

No abstract available

Figures

The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
Finkelstein DI, Billings JL, Adlard PA, Ayton S, Sedjahtera A, Masters CL, Wilkins S, Shackleford DM, Charman SA, Bal W, Zawisza IA, Kurowska E, Gundlach AL, Ma S, Bush AI, Hare DJ, Doble PA, Crawford S, Gautier EC, Parsons J, Huggins P, Barnham KJ, Cherny RA. Finkelstein DI, et al. Acta Neuropathol Commun. 2017 Jun 28;5(1):53. doi: 10.1186/s40478-017-0456-2. Acta Neuropathol Commun. 2017. PMID: 28659169 Free PMC article.

1. Finkelstein DI, Billings JL, Adlard PA, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease. Acta Neuropathol Commun. 2017;5:53. doi: 10.1186/s40478-017-0456-2. - DOI - PMC - PubMed